Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 310

Results For "C"

10164 News Found

Mitsui Chemicals begins sale of i-TFC luminous II dental material range
News | November 07, 2024

Mitsui Chemicals begins sale of i-TFC luminous II dental material range

The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range


Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
News | November 07, 2024

Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro

The company uses iPS cells to develop treatments for diseases relating to the kidney


Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr
News | November 07, 2024

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024


Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr
News | November 07, 2024

Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr

Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024


Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
News | November 07, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter


Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
News | November 07, 2024

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25


Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
Clinical Trials | November 07, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM


Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.